IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$9.44
0.24 (2.61%)
▲
5d:
+21.18%
30d:
+30.57%
90d:
+32.21%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Distribution
None View Scanner →
Strength: 9.7/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: IBRX is 13.2% above its trading range ($8.34). Market expects 5.5% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: IBRX is 13.2% above its trading range ($8.34). Market expects 5.5% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $9.44, which is considered extended relative to its 30-day fair value range of $6.91 to $8.34. From a valuation perspective, the stock is trading at a premium (Forward PE: 157.3) compared to its historical average (134.0). At these levels, the market is pricing in 5.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IBRX is in a downtrend. The price is approaching resistance at $9.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IBRX is in a downtrend. The price is approaching resistance at $9.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.91 -
$8.34
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
Protect Your Profits
IBRX is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+13.2% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 37.7% below Wall St target ($13.00)
- NEUTRAL: Trading at premium valuation - market expects 5.5% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$6.91 -
$8.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.00
Resistance Level
$9.60
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
157.33
Wall Street Target
$13.00
(+37.7%)
Revenue Growth (YoY)
167.6%
Valuation Premium vs History
+5.5% premium
PE vs Historical
157.3 vs 134.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.5%
(market-implied from PE analysis)
1-Year Target
$9.96
(+6%)
2-Year Target
$10.51
(+11%)
3-Year Target
$11.08
(+17%)
3-Yr Target (if PE normalizes)
(PE: 157→134)
PE COMPRESSION
$9.44
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry J Simon
SELL
75000 shares
2026-02-24
Barry J Simon
SELL
165000 shares
2026-02-23
Christobel Selecky
SELL
25000 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
